Karyopharm Therapeutics unveils Phase 3 SENTRY trial data in myelofibrosis at ASCO26

Karyopharm Therapeutics unveils Phase 3 SENTRY trial data in myelofibrosis at ASCO26
Karyopharm SENTRY trial data unveiled

Karyopharm Therapeutics revealed new data from its Phase 3 SENTRY trial in myelofibrosis during a late-breaking oral presentation at ASCO26.

The company announced that the results are being published simultaneously in the Journal of Clinical Oncology by ASCO, with further details available for review in the released manuscript. This update marks a significant progression in ongoing myelofibrosis research.

Karyopharm previously reported first-quarter results and outlined key near term milestones for its cancer and myelofibrosis programs in an earlier update. The company cited progress in both its endometrial cancer and myelofibrosis pipelines in that Q1 announcement. These developments provide context for the latest Phase 3 trial data.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.